Carmustine-d8 is intended for use as an internal standard for the quantification of carmustine by GC- or LC-MS. Carmustine is a DNA alkylating agent.1,2 It inhibits cell growth and induces cell cycle arrest at the G2/M phase in C6 rat glioma cells when used at a concentration of 10 ?M.2 In vivo, carmustine (0.3 and 6.7 mg/kg per day) reduces tumor growth in a C6 rat glioma model. Carmustine (0.5 mg/kg, i.p.) also reduces the number of amyloid-β plaques and brain levels of amyloid-β (1-40) (Aβ40), as well as increases brain levels of soluble amyloid precursor protein (sAPP) in the APP/PS1 transgenic mouse model of Alzheimer’s disease.3 Formulations containing carmustine have been used in the treatment of gliomas and glioblastomas.
References:
[1]. Wasserman, T.H., Slavik, M., and Carter, S.K.Clinical comparison of the nitrosoureasCancer36(4)1258-1268(1975).
[2]. Soma, M.R., Baetta, R., De Renzis, M.R., et al.In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatinCancer Res.55(3)597-602(1995).
[3]. Hayes, C.D., Dey, D., Palavicini, J.P., et al.Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustineBMC Med.1181(2013).